• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

NeoVista

edit

NeoVista, Inc., is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50.

The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Recent Milestones

edit

• 
  NeoVista received $20M in Debt funding. (3/17/11)
  Posted 3/17/11 at 6:37pm via finsmes.com
• 
  NeoVista received $33M in Series E funding. (2/13/11)
  Posted 2/13/11 at 9:02pm via dowjones.com
• 
  NeoVista received $3M in Debt funding. (4/27/10)
  Posted 4/27/10 at 2:11pm via sec.gov
• 
  NeoVista received $41M in Series C funding. (12/8/06)
  Posted 9/17/09 at 2:01am via venturebeat.com
• 
  NeoVista received $26M in Series B funding. (9/18/06)
  Posted 9/9/09 at 6:58am via venturebeat.com
• 
  NeoVista added John N. Hendrick as President & CEO.
  Posted 3/18/11 at 3:11am
• 
  NeoVista added Tony Moses as Vice President of Marketing & Sales.
  Posted 3/18/11 at 3:11am
• 
  NeoVista added Tim Dumke as Vice President of Finance.
  Posted 3/18/11 at 3:11am

Videos

Screenshots

edit

Above: NeoVista
Uploaded: 3/18/11

Sources

1. NeoVista, a radiation treatment device maker, to raise $26M (deals.venturebeat.com) [edit]
2. NeoVista, a co. targeting age-related macular degeneration, raises $41M (deals.venturebeat.com) [edit]
3. SEC D (sec.gov) [edit]
4. NeoVista Sees $33M From Insiders For Radiation Eye Treatment (fis.dowjones.com) [edit]
5. NeoVista Receives $20M Debt Financing (finsmes.com) [edit]